Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metamorphosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Metamorphosis. Displaying page 1 of 1.
    EudraCT Number: 2014-003422-41 Sponsor Protocol Number: Rifa-Stea Start Date*: 2014-10-13
    Sponsor Name:Oulu University Hospital, Department of Internal Medicine
    Full Title: The effects of PXR activation on hepatic fat content
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004871 10024681 Liver fatty change LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-015703-13 Sponsor Protocol Number: InReTel Start Date*: 2009-12-11
    Sponsor Name:Klinik für Innere Medizin II der Klinikum Chemnitz gGmbH
    Full Title: The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension
    Medical condition: Influence of Telmisartan on insulin resistance, hypertension, non-alcoholic fatty liver
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension LLT
    12.0 10052066 Metabolic syndrome LLT
    12.0 10022489 Insulin resistance LLT
    12.0 10016261 Fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018091-34 Sponsor Protocol Number: CICL670AGR02 Start Date*: 2010-07-14
    Sponsor Name:Novartis (Hellas) S.A.C.I
    Full Title: A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia pa...
    Medical condition: Chronic iron overload in patients cardiac iron overload and β thalassemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043389 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003474-31 Sponsor Protocol Number: COAV101B12301 Start Date*: 2023-06-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 1...
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022629-14 Sponsor Protocol Number: CLDE225A2201 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma
    Medical condition: locally advanced or metastatic basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10066495 Basal cell carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GR (Prematurely Ended) GB (Prematurely Ended) ES (Completed) NL (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004092-23 Sponsor Protocol Number: CLCI699C2302 Start Date*: 2016-04-29
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s d...
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) BE (Completed) PL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001177-90 Sponsor Protocol Number: CAIN457P12301 Start Date*: 2020-01-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolera...
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GR (Completed) SE (Completed) CZ (Completed) BG (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003906-29 Sponsor Protocol Number: CLCZ696G2301E1 Start Date*: 2021-02-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter study to evaluate the long-term safety and tolerability of open-label LCZ696 in patients with acute myocardial infarction who previously participated in CLCZ696G2301 (PARADISE-MI)
    Medical condition: Left ventricular dysfunction following an acute myocardial infarction and/or pulmonary congestion requiring intravenous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GR (Prematurely Ended) NO (Ongoing) CZ (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004813-42 Sponsor Protocol Number: CACZ885V2201C Start Date*: 2019-09-24
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)
    Medical condition: stages AJCC v.8 IB-IIIA non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002660-27 Sponsor Protocol Number: CINC280I12201 Start Date*: 2019-12-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally adva...
    Medical condition: non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) BE (Completed) ES (Completed) GR (Completed) DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015459-25 Sponsor Protocol Number: CTKI258A2302 Start Date*: 2010-12-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angioge...
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038410 Renal cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) BE (Completed) ES (Completed) HU (Completed) SK (Completed) IT (Completed) DE (Completed) SE (Completed) AT (Completed) GR (Completed) GB (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2014-004928-21 Sponsor Protocol Number: CINC424A2353 Start Date*: 2016-01-27
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations
    Medical condition: Early Myelofibrosis patients with high molecular risk mutations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) HU (Completed) GR (Completed) FR (Prematurely Ended) PT (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002154-20 Sponsor Protocol Number: CLCZ696G2301 Start Date*: 2017-03-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk ...
    Medical condition: Left ventricular dysfunction following an acute myocardial infarction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) AT (Completed) SK (Completed) NL (Completed) ES (Completed) HU (Completed) BE (Completed) DK (Completed) SE (Completed) FI (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002899-25 Sponsor Protocol Number: CQVM149B2302 Start Date*: 2015-12-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, 52-week, double-blind, parallel-group, active-controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) DE (Completed) SK (Completed) PT (Completed) AT (Completed) HU (Completed) NL (Completed) FI (Completed) BE (Completed) ES (Completed) DK (Completed) LV (Completed) GR (Completed) FR (Completed) BG (Completed) IE (Completed) HR (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002480-26 Sponsor Protocol Number: CACZ885V2301 Start Date*: 2018-12-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subje...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) DE (Completed) FR (Completed) ES (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003197-28 Sponsor Protocol Number: CQBW251B2201 Start Date*: 2019-08-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10029972 Obstructive airways disease (chronic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) BE (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) GR (Completed) HU (Completed) IT (Ongoing) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-000839-28 Sponsor Protocol Number: CQGE031C2302 Start Date*: 2018-08-30
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) ...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DK (Completed) ES (Completed) DE (Completed) SE (Completed) AT (Completed) GR (Completed) CZ (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001931-36 Sponsor Protocol Number: CLEE011E2301 Start Date*: 2014-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the t...
    Medical condition: premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) IT (Completed) PT (Completed) PL (Completed) BG (Completed) ES (Completed) GR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA